Maurizio Pocchiari

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5874216/publications.pdf

Version: 2024-02-01

181 12,193 49 papers citations h-index

189 189 189 5673
all docs docs citations times ranked citing authors

106

g-index

#	Article	IF	CITATIONS
1	Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases. Brain, 2022, 145, 700-712.	7.6	16
2	Validation of Revised International Creutzfeldt-Jakob Disease Surveillance Network Diagnostic Criteria for Sporadic Creutzfeldt-Jakob Disease. JAMA Network Open, 2022, 5, e2146319.	5.9	28
3	Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurology, The, 2021, 20, 235-246.	10.2	151
4	The importance of ongoing international surveillance for Creutzfeldt–Jakob disease. Nature Reviews Neurology, 2021, 17, 362-379.	10.1	69
5	Spatial Epidemiology of Sporadic Creutzfeldt-Jakob Disease in Apulia, Italy. Neuroepidemiology, 2020, 54, 83-90.	2.3	6
6	Ring trial of 2nd generation RTâ€QuIC diagnostic tests for sporadic CJD. Annals of Clinical and Translational Neurology, 2020, 7, 2262-2271.	3.7	27
7	Comparison between plasma and cerebrospinal fluid biomarkers for the early diagnosis and association with survival in prion disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1181-1188.	1.9	34
8	Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurology, The, 2020, 19, 840-848.	10.2	42
9	The Amyloid Aggregation Study on Board the International Space Station, an Update. Aerotecnica Missili & Spazio, 2020, 99, 141-148.	0.9	1
10	Transmission of CJD from nasal brushings but not spinal fluid or RTâ€QuIC product. Annals of Clinical and Translational Neurology, 2020, 7, 932-944.	3.7	23
11	Diagnostic Accuracy of Prion Disease Biomarkers in latrogenic Creutzfeldt-Jakob Disease. Biomolecules, 2020, 10, 290.	4.0	10
12	Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases. Molecular Neurobiology, 2019, 56, 2811-2821.	4.0	20
13	αâ€Synuclein RTâ€QulC assay in cerebrospinal fluid of patients with dementia with Lewy bodies. Annals of Clinical and Translational Neurology, 2019, 6, 2120-2126.	3.7	87
14	Clinicopathological features of the rare form of Creutzfeldt-Jakob disease in R208H-V129V PRNP carrier. Acta Neuropathologica Communications, 2019, 7, 47.	5. 2	3
15	Neurofilaments in blood is a new promising preclinical biomarker for the screening of natural scrapie in sheep. PLoS ONE, 2019, 14, e0226697.	2.5	17
16	Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients. Biomolecules, 2019, 9, 800.	4.0	8
17	Clinical and neuropathological phenotype associated with the novel V189I mutation in the prion protein gene. Acta Neuropathologica Communications, 2019, 7, 1.	5.2	68
18	Age at onset of genetic (E200K) and sporadic Creutzfeldt-Jakob diseases is modulated by the <i>CYP4X1</i> gene. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1243-1249.	1.9	14

#	Article	IF	Citations
19	latrogenic Creutzfeldt-Jakob disease with Amyloid- \hat{l}^2 pathology: an international study. Acta Neuropathologica Communications, 2018, 6, 5.	5.2	79
20	Preface. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 153, ix.	1.8	0
21	Concluding remarks. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 153, 485-488.	1.8	0
22	Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and AÎ ² 42 levels. Acta Neuropathologica, 2017, 133, 559-578.	7.7	129
23	Prion Strain Characterization of a Novel Subtype of Creutzfeldt-Jakob Disease. Journal of Virology, 2017, 91, .	3.4	14
24	Extended and direct evaluation of <scp>RT</scp> â€Qu <scp>IC</scp> assays for Creutzfeldtâ€Jakob disease diagnosis. Annals of Clinical and Translational Neurology, 2017, 4, 139-144.	3.7	79
25	Diagnosis of Human Prion Disease Using Real-Time Quaking-Induced Conversion Testing of Olfactory Mucosa and Cerebrospinal Fluid Samples. JAMA Neurology, 2017, 74, 155.	9.0	176
26	[P2–442]: NEURODEGENERATIONâ€ASSOCIATED PROTEINS IN HUMAN OLFACTORY NEURONS. Alzheimer's ar Dementia, 2017, 13, P805.	nd _{0.8}	0
27	Towards an early clinical diagnosis of sporadic CJD W2 (ataxic type). Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 764-772.	1.9	33
28	Patient with rapidly evolving neurological disease with neuropathological lesions of Creutzfeldtâ€Jakob disease, Lewy body dementia, chronic subcortical vascular encephalopathy and meningothelial meningioma. Neuropathology, 2017, 37, 110-115.	1.2	5
29	Detection and Diagnosis of Prion Diseases Using RT-QuIC: An Update. Neuromethods, 2017, , 173-181.	0.3	1
30	Revisiting the Heidenhain Variant of Creutzfeldt-Jakob Disease: Evidence for Prion Type Variability Influencing Clinical Course and Laboratory Findings. Journal of Alzheimer's Disease, 2016, 50, 465-476.	2.6	65
31	Pathogenesis and Transmission of Classical and Atypical BSE in Cattle. Food Safety (Tokyo, Japan), 2016, 4, 130-134.	1.8	7
32	Advanced tests for early and accurate diagnosis of Creutzfeldt–Jakob disease. Nature Reviews Neurology, 2016, 12, 325-333.	10.1	105
33	Cerebrospinal fluid realâ€time quakingâ€induced conversion is a robust and reliable test for sporadic creutzfeldt–jakob disease: An international study. Annals of Neurology, 2016, 80, 160-165.	5.3	107
34	High-Pressure Inactivation of Transmissible Spongiform Encephalopathy Agents (Prions) in Processed Meats. Food Engineering Series, 2016, , 317-330.	0.7	1
35	Heidenhain variant in two patients with inherited V210l Creutzfeldt-Jakob disease. International Journal of Neuroscience, 2016, 126, 381-3.	1.6	14
36	Geographical distribution of sporadic Creutzfeldt-Jakob disease: analysis by municipality in Apulia between 1993 and 2014. ISEE Conference Abstracts, 2016, 2016, .	0.0	0

#	Article	IF	Citations
37	A Genome Wide Association Study Links Glutamate Receptor Pathway to Sporadic Creutzfeldt-Jakob Disease Risk. PLoS ONE, 2015, 10, e0123654.	2.5	28
38	Synthetic Scrapie Infectivity: Interaction between Recombinant PrP and Scrapie Brain-Derived RNA. Virulence, 2015, 6, 132-144.	4.4	12
39	Rethinking of doxycycline therapy in Creutzfeldt-Jakob disease. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 705-705.	1.9	10
40	The future for treating Creutzfeldt–Jakob disease. Expert Opinion on Orphan Drugs, 2015, 3, 57-74.	0.8	11
41	Detection of exosomal prions in blood by immunochemistry techniques. Journal of General Virology, 2015, 96, 1969-1974.	2.9	37
42	Creutzfeldt–Jakob disease masked by head trauma and features of Wilson's disease. International Journal of Neuroscience, 2015, 125, 312-314.	1.6	0
43	Assessment of prion reduction filters in decreasing infectivity of ultracentrifuged 263 < scp>K < / scp> scrapieâ€infected brain homogenates in "spiked―human blood and red blood cells. Transfusion, 2014, 54, 990-995.	1.6	8
44	Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2014, 13, 150-158.	10.2	157
45	Mutant PrPCJD prevails over wild-type PrPCJD in the brain of V210I and R208H genetic Creutzfeldt–Jakob disease patients. Biochemical and Biophysical Research Communications, 2014, 454, 289-294.	2.1	6
46	A Test for Creutzfeldt–Jakob Disease Using Nasal Brushings. New England Journal of Medicine, 2014, 371, 519-529.	27.0	291
47	<scp>G</scp> erstmannâ€ <scp>S</scp> trässlerâ€ <scp>S</scp> cheinker Syndrome with Variable Phenotype in a New Kindred with <scp><i>PRNP</i></scp> â€ <scp>P102L</scp> Mutation. Brain Pathology, 2014, 24, 142-147.	4.1	12
48	Identification of Misfolded Proteins in Body Fluids for the Diagnosis of Prion Diseases. International Journal of Cell Biology, 2013, 2013, 1-10.	2.5	8
49	Subtype-Specific Synaptic Proteome Alterations in Sporadic Creutzfeldt-Jakob Disease. Journal of Alzheimer's Disease, 2013, 37, 51-61.	2.6	8
50	Age at Death of Creutzfeldt-Jakob Disease in Subsequent Family Generation Carrying the E200K Mutation of the Prion Protein Gene. PLoS ONE, 2013, 8, e60376.	2.5	11
51	Increased levels of acute-phase inflammatory proteins in plasma of patients with sporadic CJD. Neurology, 2012, 79, 1012-1018.	1.1	7
52	Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt–Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. Brain, 2012, 135, 3051-3061.	7.6	135
53	Sublethal Doses of \hat{l}^2 -Amyloid Peptide Abrogate DNA-dependent Protein Kinase Activity. Journal of Biological Chemistry, 2012, 287, 2618-2631.	3.4	49
54	Chronic wasting disease and atypical forms of bovine spongiform encephalopathy and scrapie are not transmissible to mice expressing wild-type levels of human prion protein. Journal of General Virology, 2012, 93, 1624-1629.	2.9	78

#	Article	IF	CITATIONS
55	Sensitivity to Biases of Case-Control Studies on Medical Procedures, Particularly Surgery and Blood Transfusion, and Risk of Creutzfeldt-Jakob Disease. Neuroepidemiology, 2012, 39, 1-18.	2.3	27
56	Sporadic <scp>C</scp> reutzfeldt– <scp>J</scp> akob disease subtypeâ€specific alterations of the brain proteome: Impact on <scp>R</scp> ab3a recycling. Proteomics, 2012, 12, 3610-3620.	2.2	15
57	Role of proteomics in understanding prion infection. Expert Review of Proteomics, 2012, 9, 649-666.	3.0	6
58	latrogenic Creutzfeldt-Jakob Disease, Final Assessment. Emerging Infectious Diseases, 2012, 18, 901-907.	4.3	280
59	Assessing Prion Infectivity of Human Urine in Sporadic Creutzfeldt-Jakob Disease. Emerging Infectious Diseases, 2012, 18, 21-28.	4.3	22
60	Comparison of nanofiltration efficacy in reducing infectivity of centrifuged versus ultracentrifuged 263K scrapieâ€infected brain homogenates in "spiked†albumin solutions. Transfusion, 2012, 52, 953-962.	1.6	14
61	Editorial. The CNCCS, a benchmark Italian consortium for bioeconomy and an opportunity for the Istituto Superiore di SanitÃ. Annali Dell'Istituto Superiore Di Sanita, 2012, 48, 115-116.	0.4	2
62	The pathological prion protein forms ionic conductance in lipid bilayer. Neurochemistry International, 2011, 59, 168-174.	3.8	17
63	Transmission of sporadic Creutzfeldtâ€Jakob disease by blood transfusion: risk factor or possible biases. Transfusion, 2011, 51, 1556-1566.	1.6	51
64	Need to improve clinical trials in rare neurodegenerative disorders. Annali Dell'Istituto Superiore Di Sanita, 2011, 47, 55-9.	0.4	3
65	Prevalence of variant CJD in the UK. BMJ: British Medical Journal, 2009, 338, b435-b435.	2.3	7
66	PrPTSE in muscle-associated lymphatic tissue during the preclinical stage of mice infected orally with bovine spongiform encephalopathy. Journal of General Virology, 2009, 90, 2563-2568.	2.9	2
67	Oral pravastatin prolongs survival time of scrapie-infected mice. Journal of General Virology, 2009, 90, 1775-1780.	2.9	16
68	Clinical trials and methodological problems in prion diseases. Lancet Neurology, The, 2009, 8, 782.	10.2	3
69	Efficacy of phthalocyanine tetrasulfonate against mouse-adapted human prion strains. Archives of Virology, 2009, 154, 1005-1007.	2.1	10
70	Neuroinvasion of the 263K scrapie strain after intranasal administration occurs through olfactory-unrelated pathways. Acta Neuropathologica, 2009, 117, 175-184.	7.7	25
71	Incidence and spectrum of sporadic Creutzfeldt–Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classification. Acta Neuropathologica, 2009, 118, 659-671.	7.7	224
72	Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. Journal of Neurology, 2009, 256, 1620-1628.	3.6	77

#	Article	IF	CITATIONS
73	Management and prevention of human prion diseases. Current Neurology and Neuroscience Reports, 2009, 9, 423-429.	4.2	2
74	Proteomic profiling of PrP27â€30â€enriched preparations extracted from the brain of hamsters with experimental scrapie. Proteomics, 2009, 9, 3802-3814.	2.2	43
75	Genomic and post-genomic analyses of human prion diseases. Genome Medicine, 2009, 1, 63.	8.2	6
76	Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain, 2009, 132, 2659-2668.	7.6	770
77	Codon 129 polymorphism of prion protein gene in sporadic Alzheimer's disease. European Journal of Neurology, 2008, 15, 173-178.	3.3	17
78	Creutzfeldt-Jakob disease: hopes for therapy. European Journal of Neurology, 2008, 15, 435-436.	3.3	8
79	Survival in Alzheimer's Disease Is Shorter in Women Carrying Heterozygosity at Codon 129 of the <i>PRNP</i> Gene and No APOE ε4 Allele. Dementia and Geriatric Cognitive Disorders, 2008, 25, 354-358.	1.5	11
80	A novel <i>PSEN2</i> mutation associated with a peculiar phenotype. Neurology, 2008, 70, 1549-1554.	1.1	62
81	SPORADIC FATAL INSOMNIA IN A FATAL FAMILIAL INSOMNIA PEDIGREE. Neurology, 2008, 70, 884-885.	1.1	18
82	Unraveling the details of prion (con)formation(s): recent advances by mass spectrometry. Current Opinion in Drug Discovery & Development, 2008, 11, 697-707.	1.9	2
83	Cyclooxygenaseâ€2, Prostaglandin E2, and Microglial Activation in Prion Diseases. International Review of Neurobiology, 2007, 82, 265-275.	2.0	41
84	Novel Prion Protein Conformation and Glycotype in Creutzfeldt-Jakob Disease. Archives of Neurology, 2007, 64, 595.	4.5	36
85	Quantitative profiling of the pathological prion protein allotypes in bank voles by liquid chromatography–mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 849, 302-306.	2.3	16
86	Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis. Journal of Neurology, 2007, 254, 901-906.	3.6	72
87	Scrapie infectivity is quickly cleared in tissues of orally-infected farmed fish. BMC Veterinary Research, 2006, 2, 21.	1.9	14
88	Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation. Transfusion, 2006, 46, 652-658.	1.6	36
89	Inactivation of transmissible spongiform encephalopathy agents in food products by ultra high pressure–temperature treatment. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2006, 1764, 558-562.	2.3	21
90	Human transmissible spongiform encephalopathies in eleven countries: diagnostic pattern across time, 1993–2002. BMC Public Health, 2006, 6, 278.	2.9	28

#	Article	IF	Citations
91	Efficient Transmission and Characterization of Creutzfeldt–Jakob Disease Strains in Bank Voles. PLoS Pathogens, 2006, 2, e12.	4.7	201
92	Pathological prion protein in muscles of hamsters and mice infected with rodent-adapted BSE or vCJD. Journal of General Virology, 2006, 87, 251-254.	2.9	26
93	Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain, 2006, 129, 2278-2287.	7.6	283
94	Bioanalytical Diagnostic Test for Measuring Prions. , 2006, , 309-336.		0
95	Identification of the pathological prion protein allotypes in scrapie-infected heterozygous bank voles (Clethrionomys glareolus) by high-performance liquid chromatography–mass spectrometry. Journal of Chromatography A, 2005, 1081, 122-126.	3.7	41
96	Migration of dendritic cells into the brain in a mouse model of prion disease. Journal of Neuroimmunology, 2005, 165, 114-120.	2.3	39
97	Genetic prion disease: the EUROCJD experience. Human Genetics, 2005, 118, 166-174.	3.8	391
98	Creutzfeldt-Jakob disease associated with the R208H mutation in the prion protein gene. Neurology, 2005, 64, 905-907.	1.1	36
99	High incidence of genetic human transmissible spongiform encephalopathies in Italy. Neurology, 2005, 64, 1592-1597.	1.1	70
100	Mortality from Creutzfeldt–Jakob disease and related disorders in Europe, Australia, and Canada. Neurology, 2005, 64, 1586-1591.	1.1	306
101	Mortality from Human Transmissible Spongiform Encephalopathies: A Record Linkage Study. Neuroepidemiology, 2005, 24, 214-220.	2.3	4
102	KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity. Biochemical and Biophysical Research Communications, 2005, 338, 1791-1797.	2.1	44
103	Pre-symptomatic detection of prions by cyclic amplification of protein misfolding. FEBS Letters, 2005, 579, 638-642.	2.8	127
104	Trapping Prion Protein in the Endoplasmic Reticulum Impairs PrPC Maturation and Prevents PrPSc Accumulation. Journal of Biological Chemistry, 2005, 280, 685-694.	3.4	72
105	Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain, 2004, 127, 2348-2359.	7.6	244
106	Standards for the assay of Creutzfeldt–Jakob disease specimens. Journal of General Virology, 2004, 85, 1777-1784.	2.9	46
107	Prion (PrPres) Allotypes Profiling: New Perspectives from Mass Spectrometry. European Journal of Mass Spectrometry, 2004, 10, 371-382.	1.0	7
108	Regulation of intrinsic prion protein by growth factors and $tnf-\hat{l}\pm$: the role of intracellular reactive oxygen species. Free Radical Biology and Medicine, 2003, 35, 586-594.	2.9	54

#	Article	IF	Citations
109	Mortality trend from sporadic Creutzfeldt-Jakob disease (CJD) in Italy, 1993–2000. Journal of Clinical Epidemiology, 2003, 56, 494-499.	5.0	21
110	Ultra-high-pressure inactivation of prion infectivity in processed meat: A practical method to prevent human infection. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6093-6097.	7.1	82
111	Detection of Pathologic Prion Protein in the Olfactory Epithelium in Sporadic Creutzfeldt–Jakob Disease. New England Journal of Medicine, 2003, 348, 711-719.	27.0	142
112	Variable Phenotype in a P102L Gerstmann-Strässler-Scheinker Italian Family. Canadian Journal of Neurological Sciences, 2003, 30, 233-236.	0.5	21
113	Prion protein allotype profiling by mass spectrometry. Pure and Applied Chemistry, 2003, 75, 317-323.	1.9	7
114	Increased CSF levels of prostaglandin E ₂ in variant Creutzfeldt–Jakob disease. Neurology, 2002, 58, 127-129.	1.1	51
115	Variant Creutzfeldt-Jakob disease in an Italian woman. Lancet, The, 2002, 360, 997-998.	13.7	24
116	Molecular diagnostics of transmissible spongiform encephalopathies. Trends in Molecular Medicine, 2002, 8, 273-280.	6.7	37
117	Two-dimensional mapping of three phenotype-associated isoforms of the prion protein in sporadic Creutzfeldt-Jakob disease. Electrophoresis, 2002, 23, 347-355.	2.4	40
118	BSE and variant Creutzfeldt-Jakob disease: never say never. Acta Neuropathologica, 2002, 103, 627-628.	7.7	5
119	Mutation of the PRNP gene at codon 211 in familial Creutzfeldt-Jakob disease. American Journal of Medical Genetics Part A, 2001, 103, 133-137.	2.4	16
120	A role for complement in transmissible spongiform encephalopathies. Nature Medicine, 2001, 7, 410-411.	30.7	11
121	A rapid and efficient method for the detection of point mutations of the human prion protein gene (PRNP) by direct sequencing. Journal of Neuroscience Methods, 2000, 99, 59-63.	2.5	13
122	Increased Brain Synthesis of Prostaglandin E ₂ and F ₂ -lsoprostane in Human and Experimental Transmissible Spongiform Encephalopathies. Journal of Neuropathology and Experimental Neurology, 2000, 59, 866-871.	1.7	96
123	Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt–Jakob disease. Neurology, 2000, 55, 811-815.	1.1	432
124	Ancestral Origins and Worldwide Distribution of the PRNP 200K Mutation Causing Familial Creutzfeldt-Jakob Disease. American Journal of Human Genetics, 1999, 64, 1063-1070.	6.2	85
125	Expression of wild-type and V210I mutant prion protein in human neuroblastoma cells. Neuroscience Letters, 1999, 270, 41-44.	2.1	11
126	Prion protein glycotype analysis in familial and sporadic Creutzfeldt-Jakob disease patients. Brain Research Bulletin, 1999, 49, 429-433.	3.0	36

#	Article	IF	Citations
127	Epidemic of transmissible spongiform encephalopathy in sheep and goats in Italy. Lancet, The, 1999, 353, 560-561.	13.7	33
128	Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. Lancet, The, 1999, 353, 1673-1674.	13.7	203
129	Creutzfeldt-Jakob Disease Mortality in Italy, 1982–1996. Neuroepidemiology, 1999, 18, 92-100.	2.3	7
130	Transmission of the 263K scrapie strain by the dental route. Journal of General Virology, 1999, 80, 3043-3047.	2.9	83
131	Diagnosis of Creutzfeldt-Jakob disease. BMJ: British Medical Journal, 1999, 318, 538-538.	2.3	12
132	Descriptive epidemiology of Creutzfeldtâ€Jakob disease in six european countries, 1993–1995. Annals of Neurology, 1998, 43, 763-767.	5. 3	154
133	High incidence of Creutzfeldt-Jakob disease in rural Calabria, Italy. Lancet, The, 1998, 352, 1989-1990.	13.7	33
134	Fatal familial insomnia in a new Italian kindred. Neurology, 1998, 51, 1491-1494.	1.1	24
135	Phenotypic Variability of Gerstmann-Straussler-Scheinker Disease is Associated with Prion Protein Heterogeneity. Journal of Neuropathology and Experimental Neurology, 1998, 57, 979-988.	1.7	182
136	Recent Italian FFI Cases. Brain Pathology, 1998, 8, 564-566.	4.1	8
137	Amyloidogenesis in Transmissible Spongiform Encephalopathies. , 1998, , 245-252.		0
138	Highly Infectious Purified Preparations of Disease-Specific Amyloid of Transmissible Spongiform Encephalopathies Are Not Devoid of Nucleic Acids of Viral Size. Intervirology, 1997, 40, 238-246.	2.8	49
139	Alpha1 antichymotrypsin signal peptide polymorphism in sporadic Creutzfeldt–Jakob disease. Neuroscience Letters, 1997, 227, 140-142.	2.1	9
140	Identification of the prion protein allotypes which accumulate in the brain of sporadic and familial Creutzfeldt-Jakob disease patients. Nature Medicine, 1997, 3, 521-525.	30.7	58
141	A new variant of Creutzfeldt-Jakob disease in the UK. Lancet, The, 1996, 347, 921-925.	13.7	2,554
142	Codon 200 mutation in a new family of Chilean origin with Creutzfeldt-Jakob disease Journal of Neurology, Neurosurgery and Psychiatry, 1996, 61, 111-112.	1.9	6
143	Polymorphism at codon 129 or codon 219 of PRNP and clinical heterogeneity in a previously unreported family with Gerstmann-Straussler-Scheinker disease (PrP-P102L mutation). Neurology, 1996, 47, 734-741.	1.1	60
144	Effect of Amphotericin B on Different Experimental Strains of Spongiform Encephalopathy Agents. , $1996,$, $271-281$.		0

#	Article	IF	Citations
145	Problems in the Evaluation of Theoretical Risks for Humans to Become Infected with BSE-Contaminated Bovine-Derived Pharmaceutical Products., 1996,, 375-383.		O
146	Tissue Handling in Suspected Creutzfeldtâ€Jakob Disease (CJD) and Other Human Spongiform Encephalopathies (Prion Diseases). Brain Pathology, 1995, 5, 319-322.	4.1	103
147	Apolipoprotein E in sporadic and familial Creutzfeldt-Jakob disease. Neuroscience Letters, 1995, 199, 95-98.	2.1	39
148	Proteinase-resistant protein in human neuroblastoma cells infected with brain material from Creutzfeldt-Jakob patient. Lancet, The, 1995, 345, 594-595.	13.7	46
149	Creutzfeldt-Jakob disease in Europe. Lancet, The, 1995, 346, 898.	13.7	33
150	Characterisation of antisera raised against species-specific peptide sequences from scrapie-associated fibril protein and their application for post-mortem immunodiagnosis of spongiform encephalopathies. Archives of Virology, 1994, 136, 99-110.	2.1	16
151	Polymorphisms of the prion protein gene in Italian patients with Creutzfeldt-Jakob disease. Human Genetics, 1994, 94, 375-9.	3.8	80
152	Detection of proteinase-resistant protein (PrP) in small brain tissue samples from Creutzfeldt-Jakob disease patients. Journal of the Neurological Sciences, 1994, 124, 171-173.	0.6	25
153	Immunodiagnosis of bovine spongiform encephalopathy. Livestock Science, 1994, 38, 41-46.	1.2	4
154	Progressive Dementia in a Young Patient with a Homozygous Deletion of the PrP Gene Annals of the New York Academy of Sciences, 1994, 724, 358-360.	3.8	5
155	Prions and related neurological diseases. Molecular Aspects of Medicine, 1994, 15, 195-291.	6.4	7 5
156	Incidence of Creutzfeldt-Jakob disease In Europe in 1993. Lancet, The, 1994, 343, 918.	13.7	34
157	Small virus-like structure in brains from cases of sporadic and familial Creutzfeldt-Jakob disease. Lancet, The, 1994, 344, 923-924.	13.7	19
158	A new point mutation of the prion protein gene in Creutzfeldtâ€Jakob disease. Annals of Neurology, 1993, 34, 802-807.	5.3	104
159	Failure to Ameliorate Creutzfeldt-Jakob Disease with Amphotericin B Therapy. Journal of Infectious Diseases, 1992, 165, 784-785.	4.0	60
160	Creutzfeldt-Jakob disease after non-commercial dura mater graft. Lancet, The, 1992, 340, 614-615.	13.7	32
161	Amphotericin B treatment dissociates in vivo replication of the scrapie agent from PrP accumulation. Nature, 1992, 356, 598-601.	27.8	166
162	Experimental drug treatment of scrapie: A pathogenetic basis for rationale therapeutics. European Journal of Epidemiology, 1991, 7, 556-561.	5.7	14

#	Article	IF	CITATIONS
163	Creutzfeldt-jakob disease in Italy. European Journal of Epidemiology, 1991, 7, 713-4.	5 . 7	1
164	Measurement of the concentration of amphotericin B in brain tissue of scrapie-infected hamsters with a simple and sensitive method. Antimicrobial Agents and Chemotherapy, 1991, 35, 1486-1488.	3.2	12
165	Combination Ultrafiltration and 6 MUrea Treatment of Human Growth Hormone Effectively Minimizes Risk from Potential Creutzfeldt-Jakob Disease Virus Contamination. Hormone Research, 1991, 35, 161-166.	1.8	44
166	Possible Implications of the Cellular Component of the Immune System in the Pathogenesis of Unconventional Slow Virus Infections., 1990,, 135-149.		2
167	Amphotericin B: A Novel Class of Antiscrapie Drugs. Journal of Infectious Diseases, 1989, 160, 795-802.	4.0	53
168	Levels of infectivity in the blood throughout the incubation period of hamsters peripherally injected with scrapie. Archives of Virology, 1989, 108, 145-149.	2.1	60
169	THE NUCLEUS BASALIS OF MEYNERT IN PARKINSONISM–DEMENTIA OF GUAM: A MORPHOMETRIC STUDY. Neuropathology and Applied Neurobiology, 1989, 15, 193-206.	3.2	8
170	Transmission of Creutzfeldt-Jakob Disease by Dural Cadaveric Graft. Journal of Neurosurgery, 1989, 71, 954-5.	1.6	92
171	Can potential hazard of Creutzfeldt-Jakob disease infectivity be reduced in the production of human Growth Hormone?. Archives of Virology, 1988, 98, 131-135.	2.1	16
172	A retrospective study of Creutzfeldt-Jakob disease in Italy (1972?1986). European Journal of Epidemiology, 1988, 4, 482-487.	5.7	20
173	The scrapie agent and the prion hypothesis. Trends in Biochemical Sciences, 1988, 13, 309-313.	7.5	15
174	Molecular forms of cholinesterases in CSF of Alzheimer's disease/senile dementia of Alzheimer type patients and matched neurological controls. Life Sciences, 1986, 38, 561-567.	4.3	15
175	Serotoninergic System in Scrapie-Infected Hamsters. Journal of Neurochemistry, 1985, 44, 862-868.	3.9	9
176	Isonicotinic hydrazide causes seizures in scrapie-infected hamstesr with shorter latency than in control animals: A possible GABAergic defect. Brain Research, 1985, 326, 117-123.	2.2	9
177	Plasma levels of 13,14-dihydro-15-keto PGE2 after vaginal application of a new PGE2 film. Prostaglandins, 1985, 29, 269-272.	1.2	9
178	Choline acetyltransferase activity and [3H]quinuclidinylbenzilate binding in brains of scrapie-infected hamsters. Neuroscience Letters, 1984, 51, 87-92.	2.1	11
179	Creutzfeldt-Jakob disease in the province of Siena: Two cases transmitted to monkeys. Italian Journal of Neurological Sciences, 1983, 4, 61-64.	0.1	4
180	Ultrastructural studies in synaptic formations in dissociated fetal mouse brain cultures. Neuroscience Letters, 1983, 43, 127-130.	2.1	5

#	Article	IF	CITATIONS
181	Peripheral neuropathy in the course of progressive systemic sclerosis: Light and ultrastructural study. Italian Journal of Neurological Sciences, 1982, 3, 341-348.	0.1	15